Skip to main content
Erschienen in: Tumor Biology 6/2013

01.12.2013 | Research Article

The VDR gene FokI polymorphism and ovarian cancer risk

verfasst von: Hui Xu, Su Li, Jian-Qing Qiu, Xiao-Lin Gao, Ping Zhang, Yong-Xia Yang

Erschienen in: Tumor Biology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

The polymorphism of vitamin D receptor (VDR) gene is demonstrated to affect the activity of its encoding protein and the subsequent downstream effects mediated by vitamin D. Mutations in VDR gene FokI have been suggested in the development of various cancers. Whether the polymorphism of the VDR gene FokI confers risk to ovarian cancer still remains controversial across the published studies in different ethnicity. The aim of this meta-analysis was to determine the role of VDR gene FokI variant in the susceptibility to ovarian cancer. Six publications with 14 individual case–control studies involving a total of 10,964 subjects were finally included into our study after a comprehensive literature search of the PubMed, Embase, Web of Science, and Wanfang databases. The strength of the association between the VDR gene FokI polymorphism and ovarian cancer risk was estimated under the allelic (T vs. C), homozygous (TT vs. CC), additive (CT vs. CC), recessive (TT vs. CC + CT), and dominant (CT + TT vs. CC) gene models. The overall odds ratios (ORs) for the contrast models of T vs. C, TT vs. CC, CT vs. CC, and CT + TT vs. CC indicated that the VDR gene FokI variant was related to an increased risk of ovarian cancer (ORT vs. C = 1.09, 95 % confidence interval (CI) 1.03–1.15, P OR = 0.004; ORTT vs. CC = 1.17, 95 % CI 1.04–1.32, P OR = 0.011; ORCT vs. CC = 1.10, 95 % CI 1.01–1.20, P OR = 0.027; ORCT + TT vs. CC = 1.12, 95 % CI 1.03–1.21, P OR = 0.007). The stratified analysis among the Caucasians also identified a significant association between the VDR gene FokI polymorphism and the susceptibility to ovarian cancer. The present meta-analysis with large available published data has revealed that the VDR gene FokI polymorphism confers susceptibility to ovarian cancer, particularly among the Caucasian population.
Literatur
1.
Zurück zum Zitat Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–37.PubMedCrossRef Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–37.PubMedCrossRef
3.
Zurück zum Zitat Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin N Am. 2012;26:1–12.CrossRef Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin N Am. 2012;26:1–12.CrossRef
4.
Zurück zum Zitat Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367–79.PubMedCrossRef Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367–79.PubMedCrossRef
5.
Zurück zum Zitat Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor—a review. Placenta. 2008;29 Suppl B:169–77.PubMedCrossRef Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor—a review. Placenta. 2008;29 Suppl B:169–77.PubMedCrossRef
6.
Zurück zum Zitat Shen N, Weiderpass E, Antilla A, Goldberg MS, Vasama-Neuvonen KM, Boffetta P, et al. Epidemiology of occupational and environmental risk factors related to ovarian cancer. Scand J Work Environ Health. 1998;24:175–82.PubMedCrossRef Shen N, Weiderpass E, Antilla A, Goldberg MS, Vasama-Neuvonen KM, Boffetta P, et al. Epidemiology of occupational and environmental risk factors related to ovarian cancer. Scand J Work Environ Health. 1998;24:175–82.PubMedCrossRef
7.
Zurück zum Zitat Shields T, Gridley G, Moradi T, Adami J, Plato N, Dosemeci M. Occupational exposures and the risk of ovarian cancer in Sweden. Am J Ind Med. 2002;42:200–13.PubMedCrossRef Shields T, Gridley G, Moradi T, Adami J, Plato N, Dosemeci M. Occupational exposures and the risk of ovarian cancer in Sweden. Am J Ind Med. 2002;42:200–13.PubMedCrossRef
8.
Zurück zum Zitat Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med. 2012;271:366–78.PubMedCrossRef Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med. 2012;271:366–78.PubMedCrossRef
9.
Zurück zum Zitat Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. Front Endocrinol (Lausanne). 2012;3:58. Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. Front Endocrinol (Lausanne). 2012;3:58.
10.
Zurück zum Zitat Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16:1–9.PubMedCrossRef Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16:1–9.PubMedCrossRef
11.
Zurück zum Zitat Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut. 1992;33:1660–3.PubMedCrossRef Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut. 1992;33:1660–3.PubMedCrossRef
12.
Zurück zum Zitat Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol. 2012;18:1672–9.PubMedCrossRef Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol. 2012;18:1672–9.PubMedCrossRef
13.
Zurück zum Zitat Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30:1170–80.PubMedCrossRef Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30:1170–80.PubMedCrossRef
14.
Zurück zum Zitat Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, et al. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol. 2010;16:3016–24.PubMedCrossRef Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, et al. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol. 2010;16:3016–24.PubMedCrossRef
15.
Zurück zum Zitat McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:297–305.PubMedCrossRef McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:297–305.PubMedCrossRef
16.
Zurück zum Zitat Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4:e103.PubMedCrossRef Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4:e103.PubMedCrossRef
17.
Zurück zum Zitat Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed
18.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
19.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
20.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
21.
Zurück zum Zitat Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566–71.PubMedCrossRef Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566–71.PubMedCrossRef
22.
Zurück zum Zitat Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Agren A, et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008;260:209–15.PubMedCrossRef Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Agren A, et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008;260:209–15.PubMedCrossRef
23.
Zurück zum Zitat Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res. 2009;69:1885–91.PubMedCrossRef Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res. 2009;69:1885–91.PubMedCrossRef
24.
Zurück zum Zitat Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer. 2011;128:936–43.PubMedCrossRef Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer. 2011;128:936–43.PubMedCrossRef
25.
Zurück zum Zitat Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, et al. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol Oncol. 2012;129:173–8.PubMedCrossRef Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, et al. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol Oncol. 2012;129:173–8.PubMedCrossRef
26.
Zurück zum Zitat Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet Test Mol Biomark. 2013;17:183–7.CrossRef Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet Test Mol Biomark. 2013;17:183–7.CrossRef
27.
Zurück zum Zitat Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol. 1997;11:1165–79.PubMedCrossRef Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol. 1997;11:1165–79.PubMedCrossRef
28.
Zurück zum Zitat Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177:145–59.PubMedCrossRef Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177:145–59.PubMedCrossRef
29.
Zurück zum Zitat Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000;86:40–6.PubMedCrossRef Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000;86:40–6.PubMedCrossRef
30.
Zurück zum Zitat Kocabas A, Karaguzel G, Imir N, Yavuzer U, Akcurin S. Effects of vitamin D receptor gene polymorphisms on susceptibility to disease and bone mineral density in Turkish patients with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010;23:1289–97.PubMed Kocabas A, Karaguzel G, Imir N, Yavuzer U, Akcurin S. Effects of vitamin D receptor gene polymorphisms on susceptibility to disease and bone mineral density in Turkish patients with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010;23:1289–97.PubMed
31.
Zurück zum Zitat Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338:143–56.PubMedCrossRef Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338:143–56.PubMedCrossRef
32.
Zurück zum Zitat Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA. Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. J Steroid Biochem Mol Biol. 2004;89–90:187–93.PubMedCrossRef Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA. Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. J Steroid Biochem Mol Biol. 2004;89–90:187–93.PubMedCrossRef
34.
Zurück zum Zitat Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29:3511–36.PubMed Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29:3511–36.PubMed
35.
Zurück zum Zitat Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726–76.PubMedCrossRef Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726–76.PubMedCrossRef
36.
Zurück zum Zitat Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787–96.PubMedCrossRef Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787–96.PubMedCrossRef
37.
Zurück zum Zitat Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;92:49–59.PubMedCrossRef Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;92:49–59.PubMedCrossRef
38.
Zurück zum Zitat Cramer DW. Epidemiologic aspects of early menopause and ovarian cancer. Ann N Y Acad Sci. 1990;592:363–75. discussion 90–4.PubMedCrossRef Cramer DW. Epidemiologic aspects of early menopause and ovarian cancer. Ann N Y Acad Sci. 1990;592:363–75. discussion 90–4.PubMedCrossRef
39.
Zurück zum Zitat Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717–21.PubMed Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717–21.PubMed
40.
Zurück zum Zitat Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584–9.PubMedCrossRef Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584–9.PubMedCrossRef
41.
Zurück zum Zitat Romanowicz-Makowska H, Smolarz B, Samulak D, Michalska M, Lewy J, Burzynski M, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and ovarian cancer risk in Polish women. Eur J Gynaecol Oncol. 2012;33:406–10.PubMed Romanowicz-Makowska H, Smolarz B, Samulak D, Michalska M, Lewy J, Burzynski M, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and ovarian cancer risk in Polish women. Eur J Gynaecol Oncol. 2012;33:406–10.PubMed
42.
Zurück zum Zitat Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG, Lima CS. Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers. 2012;33:155–9.PubMedCrossRef Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG, Lima CS. Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers. 2012;33:155–9.PubMedCrossRef
43.
Zurück zum Zitat Fang Y, van Meurs JB, d’Alesio A, Jhamai M, Zhao H, Rivadeneira F, et al. Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet. 2005;77:807–23.PubMedCrossRef Fang Y, van Meurs JB, d’Alesio A, Jhamai M, Zhao H, Rivadeneira F, et al. Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet. 2005;77:807–23.PubMedCrossRef
44.
Zurück zum Zitat Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol. 2000;14:401–20.PubMedCrossRef Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol. 2000;14:401–20.PubMedCrossRef
45.
Zurück zum Zitat Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2:203–16.PubMedCrossRef Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2:203–16.PubMedCrossRef
46.
Zurück zum Zitat Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res. 1998;13:1691–9.PubMedCrossRef Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res. 1998;13:1691–9.PubMedCrossRef
47.
Zurück zum Zitat Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472–81.PubMedCrossRef Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472–81.PubMedCrossRef
48.
Zurück zum Zitat Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660–9.PubMedCrossRef Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660–9.PubMedCrossRef
Metadaten
Titel
The VDR gene FokI polymorphism and ovarian cancer risk
verfasst von
Hui Xu
Su Li
Jian-Qing Qiu
Xiao-Lin Gao
Ping Zhang
Yong-Xia Yang
Publikationsdatum
01.12.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0826-8

Weitere Artikel der Ausgabe 6/2013

Tumor Biology 6/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.